🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to health experts.

An International Health Concern

Gonorrhoea infections are increasing worldwide, with data suggesting over 82 million instances per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of growing infection rates, escalating drug resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Global Access

According to results published in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which combines a dual-drug approach. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in many developing nations.

Doctors treating patients have expressed optimism. Having a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.